BIOMAT Database Logo BIOMAT Database Logo

[Treatment of herpes simplex keratitis with Vidarabin ointment (author's transl)]. 1978

I Egerer, and P Drobec

In 20 cases of herpes simplex keratitis the efficacy of Vidarabin ointment has been tested, in 19 cases after corneal abrasion. The eyes were treated once a day and padded until the epithelial defects had closed. Thereafter the ointment was applied 4 times per day for about one week more. On the average epithelial closure had been achieved after 2.4 days, complete normalization of the epithelium after a total of 3.6 days. This therapy results in a considerable shortening of the healing process as compared to the topical use of anti-viral medication alone. From this aspect Vidarabin ointment has proved to be a valuable adjuvant.

UI MeSH Term Description Entries
D007635 Keratitis, Dendritic A form of herpetic keratitis characterized by the formation of small vesicles which break down and coalesce to form recurring dendritic ulcers, characteristically irregular, linear, branching, and ending in knoblike extremities. (Dictionary of Visual Science, 3d ed) Furrow Keratitis,Keratitis, Furrow,Dendritic Keratitides,Dendritic Keratitis,Furrow Keratitides,Keratitides, Dendritic,Keratitides, Furrow
D009824 Ointments Semisolid preparations used topically for protective emollient effects or as a vehicle for local administration of medications. Ointment bases are various mixtures of fats, waxes, animal and plant oils and solid and liquid hydrocarbons. Ointment,Paste,Pastes,Salve,Unguent,Salves,Skin Ointment,Unguents,Ointment, Skin
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004361 Drug Tolerance Progressive diminution of the susceptibility of a human or animal to the effects of a drug, resulting from its continued administration. It should be differentiated from DRUG RESISTANCE wherein an organism, disease, or tissue fails to respond to the intended effectiveness of a chemical or drug. It should also be differentiated from MAXIMUM TOLERATED DOSE and NO-OBSERVED-ADVERSE-EFFECT LEVEL. Drug Tolerances,Tolerance, Drug,Tolerances, Drug
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D014740 Vidarabine A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus. Adenine Arabinoside,Ara-A,Arabinofuranosyladenine,Arabinosyladenine,9-beta-Arabinofuranosyladenine,9-beta-D-Arabinofuranosyladenine,Ara A,Vira-A,alpha-Ara A,alpha-D-Arabinofuranosyladenine,beta-Ara A,9 beta Arabinofuranosyladenine,9 beta D Arabinofuranosyladenine,Arabinoside, Adenine,Vira A,ViraA,alpha Ara A,alpha D Arabinofuranosyladenine,beta Ara A

Related Publications

I Egerer, and P Drobec
[Treatment of herpes simplex of the lid margin with vidarabin ointment (author's transl)].
March 1979, Wiener klinische Wochenschrift,
I Egerer, and P Drobec
Combined therapy (corneal abrasion and Vidarabin ointment) in the treatment of herpes simplex keratitis.
January 1979, Advances in ophthalmology = Fortschritte der Augenheilkunde = Progres en ophtalmologie,
I Egerer, and P Drobec
[Adenine arabinoside in herpes simplex keratitis (author's transl)].
February 1979, La Nouvelle presse medicale,
I Egerer, and P Drobec
[Results with IDU ointment in herpes simplex keratitis].
March 1963, Rinsho ganka. Japanese journal of clinical ophthalmology,
I Egerer, and P Drobec
[Pathogenesis and therapy of herpes simplex keratitis (author's transl)].
January 1975, Therapeutische Umschau. Revue therapeutique,
I Egerer, and P Drobec
[Herpes simplex keratitis treated with interferon inducer poly I:C (author's transl)].
November 1981, [Zhonghua yan ke za zhi] Chinese journal of ophthalmology,
I Egerer, and P Drobec
[Adenine-arabinoside in the treatment of idu-resistant herpes simplex keratitis (author's transl)].
March 1979, Journal francais d'ophtalmologie,
I Egerer, and P Drobec
[Herpes Simplex Keratitis under the Scanning lectron Microscope(author's transl)].
January 1975, Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. Albrecht von Graefe's archive for clinical and experimental ophthalmology,
I Egerer, and P Drobec
[Studies on immunotherapy for the experimental herpes simplex keratitis (author's transl)].
June 1980, Nippon Ganka Gakkai zasshi,
I Egerer, and P Drobec
[Herpes simplex (author's transl)].
January 1976, Padiatrie und Padologie,
Copied contents to your clipboard!